

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**


APPLICATION NO.: 10/814,620      ATTY. DOCKET NO.: B0801.70280US01

FILING DATE: March 31, 2004      CONFIRMATION NO.: 5444

APPLICANT: Tzianabos et al.

GROUP ART UNIT: 1644      EXAMINER: Nora Maureen Rooney

Sheet 1 of 7



## **U.S. PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		3,849,550		Teitelbaum et al.	11-19-1974
		4,619,995		Hayes	10-28-1986
		4,819,617		Goldberg et al.	04-11-1989
		4,886,787		de Belder et al.	12-12-1989
		4,937,270		Hamilton et al.	06-26-1990
		5,126,141		Henry	06-30-1992
		5,130,417		Stanley et al.	07-14-1992
		5,140,016		Goldberg et al.	08-18-1992
		5,158,939		Takayama et al.	10-27-1992
		5,196,510		Rodwell et al.	03-23-1993
		5,215,896		Keck et al.	06-01-1993
		5,331,573		Balaji et al.	07-19-1994
		5,514,581		Ferrari et al.	05-07-1996
		5,532,221		Huang et al	07-02-1996
		5,576,002		Jennings et al.	11-19-1996
		5,605,938		Roufa et al.	02-25-1997
		5,679,658		Elson	10-21-1997
		5,700,906		Arnot et al.	12-23-1997
		5,705,178		Roufa et al.	01-06-1998
		5,760,200		Miller et al.	06-02-1998
		5,888,741		Hendry	03-30-1999
		6,110,672		Mandel et al.	08-29-2000
		6,150,459		Mayes et al.	11-21-2000
		6,294,518		Potter et al.	09-25-2001
		6,447,765		Horwitz	09-10-2002
		6,995,237		Zimmerman, Daniel H.	02-07-2006
		7,163,683		Barstad et al.	01-16-1007

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

EXAMINER:

DATE CONSIDERED:

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/814,620	ATTY. DOCKET NO.: B0801.70280US01	
				FILING DATE: March 31, 2004	CONFIRMATION NO.: 5444	
				APPLICANT: Tzianabos et al.		
				GROUP ART UNIT: 1644	EXAMINER: Nora Maureen Rooney	
Sheet	2	of	7			

		DE	3704389	A1	Blutspendedienst Dt Rote Kreuz	08-01-1988	Y- Abstract Only
		WO	96/35433	A1	Chitogenics	11-14-1996	
		WO	95/31990	A1	Yeda Research and Development Co., Ltd	11-30-1995	
		WO	96/07427	A1	The Brigham and Women's Hospital, Inc.	03-14-1996	
		WO	96/32119	A1	Yeda Research and Development Co., Ltd.	10-17-1996	
		WO	07/092451	A2	The Brigham and Women's Hospital, Inc.	08-16-2007	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		NCBI Sequence View "Toxin" [Salmonella typhimurium LT2]. <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;id=17233414">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;id=17233414</a> , pages 1-2.	
		No Author Listed, Acute Respiratory Disease Syndrome: What is acute respiratory disease syndrome? American Lung Association. 3 pages. <a href="http://www.lungusa.org/site/apps/nlnet/content3.asp?c=dvLUK9O0E&amp;b=2058817&amp;content">http://www.lungusa.org/site/apps/nlnet/content3.asp?c=dvLUK9O0E&amp;b=2058817&amp;content</a>	
		No Author Listed, Lupus study. Meet A Lupus Researcher. <a href="http://www.lupusstudy.org/updates.php">www.lupusstudy.org/updates.php</a> . 2005;1-2.	
		No Author Listed, Polyethylene Glycols (PEGs). Accessed 3/7/05. 1 page. <a href="http://www.mindfully.org/Plastic/Polymers/Polyethylene-Glycols-PEGs.htm">http://www.mindfully.org/Plastic/Polymers/Polyethylene-Glycols-PEGs.htm</a>	
		No Author Listed, The Merck Index . Eleventh Edition 1989:734-735.	
		No Author Listed, VAXA, Systemic lupus erythematosus (SLE), damaging and unpredictable. <a href="http://www.vaxa.com/arthritis-systemic-lupus-erythematosus.cfm">http://www.vaxa.com/arthritis-systemic-lupus-erythematosus.cfm</a> . 1 page.	
		AHARONI et al., Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. 1998 Nov 2;91(1-2):135-46.	
		AHARONI et al., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10821-6.	
		AHARONI et al., Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett. 1997 Jul;58(2):79-87.	
		ARNON et al., New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol. 1996 Apr;243(4 Suppl 1):S8-13. Review.	
		BASU et al., Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconj Chem. 1997 Jul-Aug;8(4):481-8.	
		BATTA et al., Conformational stabilization of the altruronic acid residue in the O-specific polysaccharide of Shigella sonnei/Plesiomonas shigelloides. Carbohydr Res. 1997 Dec;305(1):93-9.	
		BAZAN et al., Unraveling the structure of IL-2. Science. 1992 Jul 17;257(5068):410-3.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/814,620	ATTY. DOCKET NO.: B0801.70280US01
				FILING DATE: March 31, 2004	CONFIRMATION NO.: 5444
				APPLICANT: Tzianabos et al.	
				GROUP ART UNIT: 1644	EXAMINER: Nora Maureen Rooney
Sheet	3	of	7		

	BOES et al., Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. <i>Proc Natl Acad Sci U S A</i> . 2000 Feb 1;97(3):1184-9.	
	COMSTOCK et al., Interstrain variation of the polysaccharide B biosynthesis locus of <i>Bacteroides fragilis</i> : characterization of the region from strain 638R. <i>J Bacteriol</i> . 1999 Oct;181(19):6192-6.	
	COYNE et al., <i>Bacteroides fragilis</i> NCTC9343 produces at least three distinct capsular polysaccharides: cloning, characterization, and reassignment of polysaccharide B and C biosynthesis loci. <i>Infect Immun</i> . 2000 Nov;68(11):6176-81.	
	CRABB et al., T cell regulation of <i>Bacteroides fragilis</i> -induced intraabdominal abscesses. <i>Rev Infect Dis</i> . 1990 Jan-Feb;12 Suppl 2:S178-84. Review.	
	CRAIG, Autologous hematopoietic stem cell transplantation for Crohn's disease. <i>Autoimmun Rev</i> . 2002 Aug;1(4):244-9. Review.	
	DAHIYAT et al., De novo protein design: fully automated sequence selection. <i>Science</i> . 1997 Oct 3;278(5335):82-7.	
	FRIDKIS-HARELI et al., Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. <i>J Immunol</i> . 1999 Apr 15;162(8):4697-704.	
	FRIDKIS-HARELI et al., Binding of random copolymers of three amino acids to class II MHC molecules. <i>Int Immunol</i> . 1999 May;11(5):635-41.	
	FRIDKIS-HARELI et al., Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. <i>Proc Natl Acad Sci U S A</i> . 1994 May 24;91(11):4872-6.	
	FRIDKIS-HARELI et al., Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. <i>Cell Immunol</i> . 1995 Jul;163(2):229-36.	
	GIBSON et al., Cellular mechanism of intraabdominal abscess formation by <i>Bacteroides fragilis</i> . <i>J Immunol</i> . 1998 May 15;160(10):5000-6.	
	GIBSON et al., The capsular polysaccharide complex of <i>Bacteroides fragilis</i> induces cytokine production from human and murine phagocytic cells. <i>Infect Immun</i> . 1996 Mar;64(3):1065-9.	
	GOLGHER et al., Galactofuranose-containing glycoconjugates of epimastigote and trypomastigote forms of <i>Trypanosoma cruzi</i> . <i>Mol Biochem Parasitol</i> . 1993 Aug;60(2):249-64.	
	HAFLER et al., Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. <i>J Immunol</i> . 1988 Jul 1;141(1):131-8.	
	HERTL et al., T cell control in autoimmune bullous skin disorders. <i>J Clin Invest</i> . 2006 May;116(5):1159-66. Review.	
	HIRATA et al., Cytokine synthesis of human monocytes stimulated by triple or single helical conformer of an antitumour (1-->3)-beta-D-glucan preparation, sonifilan. <i>Zentralbl Bakteriol</i> . 1998 Nov;288(3):403-13.	
	ITOKAZU et al., Abscess formation as a complication caused by postoperative osteomyelitis of the femur. <i>Arch Orthop Trauma Surg</i> . 1998;118(1-2):99-102. Review.	
	JENNINGS et al., Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. <i>J Immunol</i> . 1986 Sep 1;137(5):1708-13.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/814,620	ATTY. DOCKET NO.: B0801.70280US01
				FILING DATE: March 31, 2004	CONFIRMATION NO.: 5444
				APPLICANT: Tzianabos et al.	
				GROUP ART UNIT: 1644	EXAMINER: Nora Maureen Rooney
Sheet	4	of	7		

	JENNINGS et al., Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol. 1981 Sep;127(3):1011-8.	
	JOTWANI et al., Pathogenicity of Bacteroides fragilis group in rat intra-abdominal abscesses. Microbiol Immunol. 1992;36(10):1041-9.	
	KALKA-MOLL et al., Bacteriodes Fragilis NCTC 9343 Capsular Polysaccharide PS A and the Effect of Chain Length of T cell Proliferation. Abstracts of the 98 <sup>th</sup> Gen Mtg of the American Soc for Microbiol. 1998;98:123. Abstract B-405.	
	KASPER et al., Protective efficacy of immunization with capsular antigen against experimental infection with Bacteroides fragilis. J Infect Dis. 1979 Nov;140(5):724-31.	
	KASPER et al., Capsular polysaccharides and lipopolysaccharides from two Bacteroides fragilis reference strains: chemical and immunochemical characterization. J Bacteriol. 1983 Feb;153(2):991-7.	
	KASPER et al., Surface antigens as virulence factors in infection with Bacteroides fragilis. Rev Infect Dis. 1979 Mar-Apr;1(2):278-90.	
	KASPER et al., The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J Infect Dis. 1976 Jan;133(1):79-87.	
	KATO et al., Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother. 1995 Jun;39(6):1336-40.	
	KNETSCH et al., Polymers with tunable toxicity: a reference scale for cytotoxicity testing of biomaterial surfaces. J Biomed Mater Res A. 2007 Sep 15;82(4):947-57.	
	KNIREL et al., The structure of O-specific polysaccharides and serological classification of Pseudomonas aeruginosa (a review). Acta Microbiol Hung. 1988;35(1):3-24. Review.	
	KRAUSE et al., An inhibitor of cell proliferation associated with adhesion formation is suppressed by N,O-carboxymethyl chitosan. J Invest Surg. 1998 Mar-Apr;11(2):105-13.	
	KULICKE et al., Correlation between immunological activity, molar mass, and molecular structure of different (1-->3)-beta-D-glucans. Carbohydr Res. 1997 Jan 2;297(2):135-43.	
	KURUP et al., Antibody response to low-molecular-weight antigens of Aspergillus fumigatus in allergic bronchopulmonary aspergillosis. J Clin Microbiol. 1989 Jun;27(6):1312-6.	
	LINDBERG et al., Virulence factors in infections with bacteroides fragilis: isolation and characterization of capsular polysaccharide and lipopolysaccharide. Scand J Infect Dis Suppl. 1982;35:45-52.	
	MACONI et al., Contrast radiology, computed tomography, and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study. Amer J Gast. 2003;98(7):1545-1555.	
	MEISEL-MIKOLAJCZYK et al., Human T cell adhesion to endothelium stimulated by membrane components extracted from strains of Bacteroides vulgatus (member of B. fragilis group). Arch Immunol Ther Exp (Warsz). 1993;41(2):129-31.	
	MONTZ et al., Interleukin 10: ability to minimize postoperative intraperitoneal adhesion formation in a murine model. Fertil Steril. 1994 Jun;61(6):1136-40.	
	MOORE, The List Goes On, New Additions to the Autoimmune Disease Roster. <a href="http://autoimmunedisease.suite101.com/blog.cfm/the_list_goes_on">http://autoimmunedisease.suite101.com/blog.cfm/the_list_goes_on</a> . Pages 1-3.	
	MULHOLLAND et al., Strategies for the control of pneumococcal diseases. Vaccine. 1999 Jul	
EXAMINER:		DATE CONSIDERED:

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/814,620	ATTY. DOCKET NO.: B0801.70280US01
				FILING DATE: March 31, 2004	CONFIRMATION NO.: 5444
				APPLICANT: Tzianabos et al.	
				GROUP ART UNIT: 1644	EXAMINER: Nora Maureen Rooney
Sheet	5	of	7		

		30;17 Suppl 1:S79-84. Review.	
		NIELSEN et al., Applications of peptide nucleic acids. Curr Opin Biotechnol. 1999 Feb;10(1):71-5. Review.	
		OHNO et al., Enhancement of LPS triggered TNF-alpha (tumor necrosis factor-alpha) production by (1-->3)-beta-D-glucans in mice. Biol Pharm Bull. 1995 Jan;18(1):126-33.	
		OHNO et al., Comparison of the immunopharmacological activities of triple and single-helical schizophyllan in mice. Biol Pharm Bull. 1995 Sep;18(9):1242-7.	
		ONDERDONK et al., The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis. 1977 Jul;136(1):82-9.	
		PANTOSTI et al., Bacteroides fragilis strains express multiple capsular polysaccharides. J Clin Microbiol. 1993 Jul;31(7):1850-5.	
		PAOLETTI et al., Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 1992 Jan;89(1):203-9.	
		PAVLIAK et al., Structural elucidation of the capsular polysaccharide of Bacteroides fragilis strain 23745M1. Carbohydr Res. 1995 Oct 2;275(2):333-41.	
		PERUMAL et al., Protective effect of interleukin-2 on experimental intra-abdominal abscess development due to Bacteriodes Fragilis. Clinical Research. 1990;38(2):550A.	
		RANUA et al., Serum IgA, IgG, and IgM concentrations in patients with epilepsy and matched controls: a cohort-based cross-sectional study. Epilepsy Behav. 2005 Mar;6(2):191-5.	
		REED et al., A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493-497.	
		RIESENFELD et al., Biosynthesis of heparin. Assay and properties of the microsomal N-acetyl-D-glucosaminyl N-deacetylase. J Biol Chem. 1980 Feb 10;255(3):922-8.	
		RYPENS et al., Percutaneous drainage of abdominal abscesses in pediatric Crohn's disease. AJR Am J Roentgenol. 2007 Feb;188(2):579-85.	
		SCHLEGEL et al., A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5061-6. Erratum in: Proc Natl Acad Sci U S A 1996 aUG 6;93(16):8796.	
		SCHNEIDER et al., De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J Comput Aided Mol Des. 2000 Jul;14(5):487-94.	
		SEGAL et al., Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. Pediatr Diabetes. 2008 Jun;9(3 Pt 1):250-4.	
		SELLIN et al., Conformational analysis of a toxic peptide from Trimeresurus wagleri which blocks the nicotinic acetylcholine receptor. Biophys J. 1996 Jan;70(1):3-13.	
		SHAPIRO et al., Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to Bacteroides fragilis. J Immunol. 1986 Jul 1;137(1):341-6.	
		SHAPIRO et al., Cellular immunity to Bacteroides fragilis capsular polysaccharide. J Exp Med. 1982 Apr 1;155(4):1188-97.	
		SIMMONS et al., Synthesis and membrane permeability of PNA-peptide conjugates. Bioorg Med	
EXAMINER:		DATE CONSIDERED:	

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/814,620	ATTY. DOCKET NO.: B0801.70280US01
				FILING DATE: March 31, 2004	CONFIRMATION NO.: 5444
				APPLICANT: Tzianabos et al.	
				GROUP ART UNIT: 1644	EXAMINER: Nora Maureen Rooney
Sheet	6	of	7		

		Chem Lett. 1997;7(23):3001-6.	
		STEIN et al., Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992 Jun;165 Suppl 1:S49-52. Review.	
		TEITELBAUM et al., Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3842-7.	
		TEITELBAUM et al., Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9724-8.	
		TEITELBAUM et al., Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):137-41.	
		TEITELBAUM et al., Unprimed spleen cell populations recognize macrophage-bound antigen with opposite net electric charge. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1693-6.	
		TZIANABOS et al., Bacterial structure and functional relation to abscess formation. Infect Agents Dis. 1994 Oct;3(5):256-65. Review.	
		TZIANABOS et al., Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection. Arch Surg. 1999 Nov;134(11):1254-9.	
		TZIANABOS et al., IL-2 mediates protection against abscess formation in an experimental model of sepsis. J Immunol. 1999 Jul 15;163(2):893-7.	
		TZIANABOS et al., Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators. J Infect Dis. 1998 Jul;178(1):200-6.	
		TZIANABOS et al., Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. Clin Infect Dis. 1995 Jun;20 Suppl 2:S132-40. Review.	
		TZIANABOS et al., Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect Immun. 1994 Aug;62(8):3590-3.	
		TZIANABOS et al., T Cell Activation by Zwitterionic polysaccharides and peptide mimetics prevents antrabdominal abscess formation. Abstracts of the 99 <sup>th</sup> General Meeting of the American Society for Microbiology. Chicago, US: May 30- June 3, 1999. 28 June 1999;99:37-38.	
		TZIANABOS et al., Structural basis for polysaccharide-mediated protection against intraabdominal abscess formation. 94 <sup>th</sup> ASM General Meeting. May 23-27, 1994. Las Vegas, Nevada. Abstract B-206:65.	
		TZIANABOS et al., Characteristics of bacterial polysaccharides that activate T cells. The International Carbohydrate Symposium XVII. July 21, 1994.	
		VIRET et al., Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol Microbiol. 1993 Jan;7(2):239-52.	
		WANG et al., Structure characterization of an abscessogenic capsular polysaccharide from Bacteriodes fragilis by NMR spectroscopy. XIX International Conference of NMR in Biological Systems. Florence, Italy. August 20-25, 2000. Abstract.	
		WEHR et al., Anti-low-density lipoprotein antibodies in alcoholics without and with liver disease and in social drinkers. Alcohol Alcohol. 1997 Jan-Feb;32(1):43-9.	
		WUJEK et al., A carbohydrate polymer that effectively prevents epidural fibrosis at laminectomy sites in the rat. Exp Neurol. 1991 Nov;114(2):237-45.	
EXAMINER:		DATE CONSIDERED:	

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/814,620	ATTY. DOCKET NO.: B0801.70280US01
				FILING DATE: March 31, 2004	CONFIRMATION NO.: 5444
				APPLICANT: Tzianabos et al.	
				GROUP ART UNIT: 1644	EXAMINER: Nora Maureen Rooney
Sheet	7	of	7		

		YOKOYAMA et al., Adhesion behavior of rat lymphocytes to poly(ether)-poly(amino acid) block and graft copolymers. J Biomed Mater Res. 1986 Sep;20(7):867-78.	
		YOSHII, Cytotoxic effects of acrylates and methacrylates: relationships of monomer structures and cytotoxicity. J Biomed Mater Res. 1997 Dec 15;37(4):517-24.	
		ZALEZNIK et al., A soluble suppressor T cell factor protects against experimental intraabdominal abscesses. J Clin Invest. 1985 Mar;75(3):1023-7.	
		ZHU et al., Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol. 2007 Jan;122(1):75-84. Epub 2006 Oct 11.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.